

Neurolix Establishes Office in Castres, France

Dana Point (CA) and Castres (France), 01 July, 2014 – Neurolix Inc. announced today that it has established a subsidiary in France. The main purpose of the subsidiary is to facilitate interaction with European biotechnology, pharmaceutical research and development and investment communities.

The subsidiary, Neurolix SAS, is based at a ‘start-up incubator’ in Castres, near the regional center of Toulouse. Neurolix SAS will provide the contact point for collaborations with researchers at several European academic institutions, including Prof. Angela Cenci in Lund (Sweden), Prof. Julian Paton in Bristol (UK), Prof. Luc Zimmer in Lyon (France) and Prof. Francesc Artigas in Barcelona (Spain), as well as researchers at Contract Research Organizations (CROs) such as Dr. Andrew McCreary at BrainsOnline in Groningen (The Netherlands).

In addition to facilitating European collaborations, the French subsidiary will interact with French and European investment communities. Dr. Adrian Newman-Tancredi, Chief Scientific Officer of Neurolix Inc. and President of Neurolix SAS, commented, “We believe that the French biotechnology sector is experiencing rapid growth thanks to government-led initiatives, such as the Research Tax Credit (*Crédit Impôt Recherche*) which provides a significant boost to start-up companies. These initiatives will facilitate the advancement of Neurolix’ projects over coming years.”

Mark Varney, President and CEO of Neurolix Inc. added: “We are excited about our prospects going forward as a transatlantic company. This will increase our networking capacity with international collaborators.”

About Neurolix, Inc.

Neurolix, located in Dana Point, California, is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of neurological disorders such as Rett syndrome and Parkinson’s disease, and psychiatric disorders such as depression and schizophrenia. Additional information regarding Neurolix is available at <http://www.neurolix.com>.

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolix disclaims any intent or obligation to update these forward-looking statements.

PRESS CONTACTS

Dr Mark Varney, CEO Neurolix,
mvarney@neurolix.com